99% Purity Gw-0742 Sarms CAS 317318-84-6 Gw0742

99% Purity GW-0742 SARMs CAS 317318-84-6 GW0742GW-0742Product Detail:Product NameGW0742SynonymGW0742;[4-[[[2-[3-FLUORO-4-(TRIFLUOROMETHYL)PHENYL]-4-METHYL-5-THIAZOLYL]METHYL]THIO]-2-METHYLPHENOXY]ACETIC ACID;4-[2-(3-FLUORO-4-TRIFLUOROMETHYL-PHENYL)-4-METHYL-THIAZOL-5-YLMETHYLSULFANYL]-2-METHYL-PHENOXY-ACETIC ACIDCAS317318-84-6EINECS259-415-2Assay99%Appearancecrystalline solidPacking1kg net/foil bag, 5kg/drum.StandardEnterprise StandardStorageShading , Confined PreservationUsageA small molecule agonist of the human Peroxisome Proliferator-Activated Recept δ (PPAR δ). It shows an EC50 of 1.1 nM against PPAR δ with 100-fold selectivity over the other human subtypes.Molecular FomularC21H17F4NO3S2Molecular Weight471.49
CAS: 317318-84-6
Product Name: GW 0742
Alias: GW 610742, GW-0742
MF: C21H17F4NO3S2
Purity: 99.50%
Dosage: 20-30mg per day
Appearance: White powder
Brand Nmae: HKYC
Standard: USP
Usage:
GW 0742 had been investigated as a potential treatment for obesity,diabetes,dyslipidemia and cardiovascular disease
Payment terms: T/T, Western Union, Money Gram, Bitcoin
Descrption:
GW0742, also known as GW610742, is a PPAR agonist. GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons. GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. GW0742 has direct protective effects on right heart hypertrophy.GW0742 may enhance lipid metabolism in heart both in vivo and in vitro.Application:
GW 0742 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue , and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome , most likely by stimulating fatty acid oxidation .
GW0742 has been proposed as a potential treatment for obesity and related conditions , especially when used in conjunction with a synergistic compound AICAR , as the combination has been shown to significantly increase exercise endurance in human.How GW0742 Works:
The highest antagonist activity for GW0742 was found for VDR and the androgen receptor (AR). Surprisingly, GW0742 behaved as PPAR agonist/antagonist activating transcription at lower concentration and inhibiting this effect at higher concentrations. A unique spectroscopic property of GW0742 was identified as well. In the presence of rhodamine-derived molecules, GW0742+ increased fluorescence intensity and fluorescence polarization at an excitation wavelength of 595 nm and emission wavelength of 615 nm in a dose dependent manner.
The GW0742-inhibited NR-coactivator binding resulted in a reduced expression of five different NR target genes in LNCaP cells in the presence of agonist. Especially VDR target genes CYP24A1, IGFBP-3 and TRPV6 were negatively regulated by GW0742. GW0742 is the first VDR ligand inhibitor lacking the structure of VDR ligand antagonists. Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.RelatedSARMSproducts:Product nameCAS No.SpecificationOstarine(MK2866)841205-47-8/1235370-13-4/1202044-20-999%minLGD-40331165910-22-498%minMK-677159633-92-898%minAndarine (S-4)401900-40-1798%minGW-501516317318-70-098%minAICAR2627-69-298%minRAD1401182367-47-098%minSR90091379686-30-298%minYK111370003-76-1